Results 161 to 170 of about 43,533 (201)

Hyperreflective Dots on SD-OCT: Implications for Predicting Treatment Outcomes in Diabetic Macular Edema. [PDF]

Diagnostics (Basel)
Li S, Li M, Sun A, Zhang H.
europepmc   +1 more source

Diabetic Macular Edema in Maintenance Intravitreal Scheduling. [PDF]

Pharmaceutics
Vingolo EM, Calabro M, Mascolo S, Miccichè F, Casillo L, Lupo S, Menna F.   +6 more
europepmc   +1 more source

Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema in Japan. [PDF]

Clin Ophthalmol
Mizuki Y, Inokuchi S, Kuroki T, Kamata A, Onishi J, Watanabe Y, Takeda M, Meguro A, Kawagoe T, Teshigawara T, Yamada N, Mizuki N.   +11 more
europepmc   +1 more source

Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema. [PDF]

Sci Rep
Murata T, Hirano T, Ideta S, Tanaka K, Shimura M.   +4 more
europepmc   +1 more source

Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study. [PDF]

J Clin Med
Funatsu M, Higashijima F, Ariyoshi N, Haraguchi A, Wasai Y, Mikuni M, Ohta M, Wakuta M, Hirano S, Yamauchi K, Kimura K.   +10 more
europepmc   +1 more source

Analysis of OCT-Based Biomarkers and Recurrence in Eyes with Diabetic Macular Edema Following Anti-VEGF Therapy. [PDF]

Int J Gen Med
Zhu T, Wang Y, Hua Y, Zha X, Xu T.
europepmc   +1 more source

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report. [PDF]

Ophthalmol Sci
Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG.   +21 more
europepmc   +1 more source

Future horizons in diabetic macular edema management: nanocarriers as a promising alternative to conventional anti-VEGF therapy. [PDF]

Ann Med Surg (Lond)
Ammer R, Khan MW, Hanan M, Talha M, Fatima M.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Diabetic macular edema

Disease-a-Month, 2021
Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike ...
Melissa, Ixcamey, Camille, Palma
  +6 more sources

Diabetic Macular Edema

2010
Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the center of the macula, represents the most common cause of vision loss in patients affected by diabetes mellitus. In the last few years, many diagnostic tools have proven to be useful in the detection and the monitoring of the features characterizing DME.
Bandello, Francesco, Battaglia Parodi, Maurizio, LANZETTA, Paolo, Loewenstein, Anat, Massin, Pascale, MENCHINI, Francesca, VERITTI, Daniele   +6 more
  +11 more sources